node negative and node positive disease with one to three positive lymph nodes. 8 In addition, as MammaPrint was both developed and validated on untreated patients, it is most consistent in newly diagnosed, untreated women who present to their surgeons and oncologists for treatment advice. Women with a 'low risk' result have a 10 % risk of developing distant metastases over the next 10 years without any adjuvant hormone or chemotherapy. Thus, given the known benefit of hormonal therapy in ER-positive patients (i.e. ~50 % risk reduction), these patients are at a sufficiently low risk for recurrence so that hormone therapy alone is optimal treatment. 9 Conversely, those patients with a 'high risk' result have a 30 % risk of recurrence and in addition, can be expected to benefit from both neoadjuvant 10 and/or adjuvant 11 chemotherapy.
To further evaluate the benefits of the MammaPrint profile in clinical practice, two large prospective, randomized trials are under way. The
Investigation of Serial Studies to Predict your Individual Response with
Imaging and Molecular Analysis (I-SPY2) trial was recently launched at 20 major cancer centers across the US and is designed to accelerate Phase II drug development using a novel adaptive design sanctioned by the FDA, National Cancer Institute (NCI), and a number of pharmaceutical companies. 12 The Microarray in Node-Negative Disease May Avoid Chemotherapy (MINDACT) trial is a much more ambitious undertaking that has been accruing patients for several years across the EU. It is a prospective, randomized trial to determine whether patients are better served by treatment prompted by the MammaPrint profile or by clinicopathologic assessment using the Adjuvant! Online tools. 13 It is designed to enroll 6,000 patients so that the number of patients on the discordant arm wherein genomic treatment assignment is compared with that prompted by Adjuvant! Online is sufficient to detect a clinically meaningful and statistically significant benefit.
MINDACT finished enrollment in July 2011 and will be ready for evaluation by 2014.
TargetPrint
TargetPrint was developed as an independent and quantitative measure of ER, PR, and HER2 expression using messenger RNA 
Sign Off
TargetPrint determines the mRNA levels of estrogen receptor (ER), progesterone receptor (PR) and HER2 using DNA microarray technology. The values of the DNA microarray read out for these three genes have been validated in over 600 breast cancer samples against conventional immunohistochemistry (IHC) and fluorescent in situ hybridization (FISH), allowing a conversion of the microarray values to IHC and FISH equivalence which are shown in the red and green. The ER, PR and HER2 microarray values were compared to IHC which was assessed at one central laboratory, indicating a 93% concordance (95CI: 91-95%) for ER, an 83% concordance (95CI: 80-86%) for PR and a 96% concordance (95CI: 94-98%) for HER2 respectively. 1 For ER and PR a threshold of 1% IHC positively stained tumor cells was used to classify samples as positive; for HER2, an IHC score of 3+ was considered positive. 
Regulatory Information
For In Vitro Diagnostic Use. Caution: Federal law restricts this device to sale by or on the order of a physician. Agendia, Inc (05D1089250) is certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA) as qualified to perform high-complexity clinical testing. TargetPrint is an aid in estimating the prognosis of patients diagnosed with breast cancer. Decisions regarding care and treatment should not be based on a single test such as this test. Rather, decisions on care and treatment should be based on the independent medical judgment of the treating physician taking into consideration all available information concerning the patient's condition, including other pathological tests, in accordance with the standard of care in a given community. TargetPrint was validated using FDA cleared test kits in a CLIA certified US reference laboratory.
This test was performed at Agendia's Irvine, California laboratory.
RNA Integrity Score: 4.5 Pathology/Additional Comments:
The reported tumor cell percentage and pathology comments serve as a quality control for Agendia's genomic assays and should not be viewed as a diagnosis of the presence or absence of malignancy. Together they not only provide prognostic information, but can also be used to help guide therapy. 5 The schema for development of BluePrint is shown in Figure 3 , samples that were analysed both by TargetPrint The specimen has been reviewed to determine the tumor cell percentage. 
Sign Off
Using DNA microarray technology, TheraPrint™ measures the mRNA level of genes that are of potential interest in the context of cancer therapy. Leveraging the chip capacity, the expression of each gene is assessed in multifold, assuring precise results. Provided is the absolute expression ( 2 log intensity) of the patient's genes ranging from 0 to 19.3. The relative expression percentile represents the patient's gene expression compared to a reference population of newly diagnosed untreated breast cancer patients (n=373) and indicates the percentage of reference samples with a lower intensity
For each TheraPrint Gene, the absolute expression is measured and compared to the reference distribution. The relative expression of the patient's gene is given as a percentile score. This percentile score indicates the percentage of reference samples with a lower intensity. For instance, a percentile score of 91 indicates that 91% of the samples in the reference distribution had intensities lower than the intensity found in the patient's sample.
The absolute expression level is the 2log of the intensity of each gene as measured on the Agilent microarrays (HD 8-pack). The measurement value ranges from 0 to 19.3 and is proportional to the expression level of the gene. However, the value cannot be directly translated to RNA concentration or copy number as there are no known cutoffs to determine whether a given expression level is truly high / low or activated / inactivated. The gene expression level of a given patient's results can only be compared to the gene expression level of all other samples in the reference distribution to provide relative interpretation of rather high or rather low.
The reference distribution was established using 373 samples from newly diagnosed breast cancer patients untreated with chemotherapy or hormonal therapy. Each of the samples was hybridized onto the Agilent HD 8-pack array, the 2 log intensity of the research panel genes was measured and the results compiled. To indicate the expression distribution of the individual gene, the reference distribution is given as the 5-95% expression range on the 0 to 19.3 2 log intensity scale.
Regulatory Information
For In Vitro Diagnostic Use Caution: Federal law restricts this device to sale by or on the order of a physician. Agendia, Inc (05D1089250) is certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA) as qualified to perform high-complexity clinical testing. Research Gene Panel is an aid to measure the mRNA expression levels of certain genes in patients diagnosed with breast cancer. Decisions regarding care and treatment should not be based on a single test such as this test. Rather, decisions on care and treatment should be based on the independent medical judgment of the treating physician taking into consideration all available information concerning the patient's condition, including other pathological tests, in accordance with the standard of care in a given community.
This test was performed at Agendia's Irvine, California laboratory. 
